Document Detail


Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.
MedLine Citation:
PMID:  8141698     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Malignant mesothelioma is a tumour which is generally resistant to chemotherapy. While the addition of interferon to chemotherapy improves response rates in some other malignancies, such a combination has not been evaluated in the treatment of mesothelioma. AIMS: To assess the anti-tumour effects and toxicity of interferon-alpha combined with doxorubicin in the treatment of pleural mesothelioma. METHODS: Twenty five patients (mean age 54 +/- 11 years) were enrolled in a phase II study. All patients had a confirmed histological diagnosis, measurable tumour, a life expectancy of at least three months, and no prior chemotherapy or interferon. Interferon alpha-2a, 9 x 10(6) U sc daily, was administered together with doxorubicin 25 mg per m2 i.v. weekly, for 12 weeks. Response status was assessed by tumour measurements on clinical examination and thoracic CT scans before and after treatment. RESULTS: A partial response was observed in four patients (16%; 90% CI, 8-30%), 11 remained stable, while six had progressive disease. Four patients withdrew within the first month because of toxicity. The median survival of all patients was 11 months (95% CI, 3-19). Dose modification as a result of toxicity was required in all patients. Lethargy, weight loss, leukopenia and vomiting were the most common side effects. CONCLUSIONS: The combination of interferon-alpha and doxorubicin showed only modest activity and was associated with significant toxicity. It cannot be recommended in the treatment of malignant pleural mesothelioma.
Authors:
J W Upham; A W Musk; G van Hazel; M Byrne; B W Robinson
Related Documents :
21768878 - The number of lymphoma-associated macrophages in tumor tissue is an independent prognos...
21680108 - High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderat...
17669808 - Visceral pleural infiltration as a negative prognostic factor in lung metastasis.
12565988 - The activity of raltitrexed (tomudex) in malignant pleural mesothelioma: an eortc phase...
16600348 - Nested variant of urothelial carcinoma: a rare presentation.
20391648 - Clinical roundtable monograph: recent advances in nhl. highlights from the 51st ash ann...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Australian and New Zealand journal of medicine     Volume:  23     ISSN:  0004-8291     ISO Abbreviation:  Aust N Z J Med     Publication Date:  1993 Dec 
Date Detail:
Created Date:  1994-04-26     Completed Date:  1994-04-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1264322     Medline TA:  Aust N Z J Med     Country:  AUSTRALIA    
Other Details:
Languages:  eng     Pagination:  683-7     Citation Subset:  IM    
Affiliation:
University Department of Medicine, Sir Charles Gairdner Hospital, Perth, WA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Combined Modality Therapy
Doxorubicin / administration & dosage*,  adverse effects
Female
Humans
Interferon Alfa-2a / administration & dosage*,  adverse effects
Male
Mesothelioma / mortality,  therapy*
Middle Aged
Pleural Neoplasms / mortality,  therapy*
Survival Rate
Chemical
Reg. No./Substance:
23214-92-8/Doxorubicin; 76543-88-9/Interferon Alfa-2a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cryptococcus neoformans in tropical northern Australia: predominantly variant gattii with good outco...
Next Document:  Computerised tomography does not predict N2 disease in patients with lung cancer.